Diez M, Favaloro L, Bertolotti A, Burgos J M, Vigliano C, Lastra M P, Levin M J, Arnedo A, Nagel C, Schijman A G, Favaloro R R
Unidad de Trasplante Intra toracico, Instituto de Cardiología y Cirugía Cardiovascular, Fundación Favaloro y Laboratorio de Biología Molecular de la Enfermedad de Chagas INGEBI-CONICET Buenos Aires, Argentina. mdiez@ffavaloro@org
Am J Transplant. 2007 Jun;7(6):1633-40. doi: 10.1111/j.1600-6143.2007.01820.x.
Heart transplantation (HTx) is a useful therapy for end-stage Chagaś cardiomyopathy; however, Chagas reactivation remains a mayor complication. Parasitological methods offer poor diagnostic sensitivity, and use of more sensitive tools such as the Polymerase chain reaction (PCR) is usually necessary. In the present study, reactivation incidence and PCR usefulness for early reactivation diagnosis, as well as for treatment response evaluation during follow-up, were analyzed using Strout parasite detection test, in 10 of 222 consecutive HTx patients suffering Chagas cardiomyopathy. PCR strategies targeted to minicircle sequences (kDNA, detection limit 1 parasite/ 10 mL blood) and miniexon genes (SL-DNA, 200 parasite/10 mL) were performed to compare parasite burdens between samples. No patients received prophylactic antiprotozoal therapy (benznidazole). Five patients (50%) exhibited clinical reactivation within a mean period of 71.6 days; positive Strout results were observed in most cases presenting clinical manifestations. kDNA-PCR was positive 38-85 days before reactivation, whereas SLDNA-PCR became positive only 7-21 days later, revealing post-HTx parasitic load enhancement present prior to clinical reactivation development. Reactivations were successfully treated with benznidazole and generated negative PCR results. Results observed in this study indicate the value of PCR testing for an early diagnosis of Chagas reactivation as well as for monitoring treatment efficacy.
心脏移植(HTx)是治疗终末期恰加斯心肌病的有效方法;然而,恰加斯病再激活仍然是一个主要并发症。寄生虫学方法的诊断敏感性较差,通常需要使用更敏感的工具,如聚合酶链反应(PCR)。在本研究中,我们使用斯特劳特寄生虫检测试验,对222例连续性恰加斯心肌病心脏移植患者中的10例进行分析,以评估再激活发生率、PCR在恰加斯病早期再激活诊断以及随访期间治疗反应评估中的作用。针对微小环序列(kDNA,检测限为每10毫升血液中有1个寄生虫)和微小外显子基因(SL-DNA,每10毫升血液中有200个寄生虫)的PCR策略用于比较样本间的寄生虫负荷。所有患者均未接受预防性抗原虫治疗(苯硝唑)。5例患者(50%)在平均71.6天内出现临床再激活;大多数出现临床表现的病例中斯特劳特检测结果呈阳性。kDNA-PCR在再激活前38 - 85天呈阳性,而SL-DNA-PCR仅在7 - 21天后呈阳性,这揭示了临床再激活发生前心脏移植后寄生虫负荷的增加。苯硝唑成功治疗了再激活病例,并使PCR结果转为阴性。本研究结果表明PCR检测在恰加斯病再激活早期诊断及监测治疗效果方面具有重要价值。